G01N 2333/521
Chemokines
G01N2333/521 (Chemokines) appears on 177 US grants and 477 published applications in this corpus.
Search patents in G01N- Granted patents
- 177
- Published applications
- 477
- Assignees
- 283
- Inventors
- 999
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 3 |
| 2005 | 0 | 2 |
| 2006 | 2 | 2 |
| 2007 | 0 | 1 |
| 2008 | 0 | 4 |
| 2009 | 2 | 4 |
| 2010 | 1 | 10 |
| 2011 | 2 | 15 |
| 2012 | 5 | 15 |
| 2013 | 5 | 17 |
| 2014 | 3 | 19 |
| 2015 | 8 | 29 |
| 2016 | 9 | 36 |
| 2017 | 13 | 30 |
| 2018 | 14 | 33 |
| 2019 | 17 | 19 |
| 2020 | 18 | 35 |
| 2021 | 10 | 28 |
| 2022 | 16 | 33 |
| 2023 | 11 | 38 |
| 2024 | 16 | 36 |
| 2025 | 16 | 31 |
| 2026 | 9 | 37 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Treatment of autoimmune liver disease15 Sep 2026US 12,736,544 B2The Governors of the University of Alberta
- Methods of treating an autoimmune disease with a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3)14 Jul 2026US 12,678,485 B2Stemline Therapeautics, Inc.
- Anti-CXCR2 antibodies and uses thereof30 Jun 2026US 12,668,639 B2Shanghaitech University
- Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status14 Apr 2026US 12,601,747 B2Bio-Rad Laboratories, Inc.
- Methods and compositions for diagnosis and prognosis of renal injury and renal failure31 Mar 2026US 12,590,975 B2Biomerieux
- Immunogenicity screening method1 Oct 2026US 2026/0298910 A1
- Multi-Analyte Rapid Diagnostic Test for Sepsis Using Novel Biomarkers and Quantum Dot Technology1 Oct 2026US 2026/0298921 A1Trimar Domestic Inc.
- Methods of treating endometriosis1 Oct 2026US 2026/0298926 A1Cedars-Sinai Medical Center
- Biomarkers of amyotrophic lateral sclerosis and uses thereof17 Sep 2026US 2026/0276655 A1
- Biomarkers for predicting cancer treatment efficacy10 Sep 2026US 2026/0266828 A1Arcus Biosciences, Inc.
Most cited
By later US patents
- Methods for treating or preventing asthma by administering an IL-4R antagonist38US 9,574,004 B2Regeneron Pharmaceuticals, Inc. · 2017
- Minimally-invasive measurement of esophageal inflammation34US 8,637,239 B2The Board of Trustees of the University of Illinois · 2014
- Systems and methods for characterizing kidney diseases29US 7,138,230 B2Renovar Incorporated · 2006
- Methods of using tumor infiltrating lymphocytes in double-refractory melanoma26US 11,433,097 B2Iovance Biotherapeutics, Inc. · 2022
- Methods of using tumor infiltrating lymphocytes in double-refractory melanoma24US 11,819,517 B2Iovance Biotherapeutics, Inc. · 2023